BioXcel Therapeutics (NASDAQ:BTAI) & Xenon Pharmaceuticals (NASDAQ:XENE) Head to Head Review

BioXcel Therapeutics (NASDAQ:BTAI) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.

Institutional and Insider Ownership

30.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 35.8% of BioXcel Therapeutics shares are held by insiders. Comparatively, 5.5% of Xenon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares BioXcel Therapeutics and Xenon Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioXcel Therapeutics	$2.40 million	10.25	-$179.05 million	($5.18)	-0.13
Xenon Pharmaceuticals	$9.43 million	327.70	-$182.39 million	($2.71)	-15.05

BioXcel Therapeutics has higher earnings, but lower revenue than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BioXcel Therapeutics and Xenon Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioXcel Therapeutics	-4,487.39%	N/A	-133.99%
Xenon Pharmaceuticals	N/A	-24.16%	-23.15%

Risk and Volatility

BioXcel Therapeutics has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for BioXcel Therapeutics and Xenon Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioXcel Therapeutics	0	2	3	0	2.60
Xenon Pharmaceuticals	0	0	9	1	3.10

BioXcel Therapeutics presently has a consensus target price of $5.50, suggesting a potential upside of 738.16%. Xenon Pharmaceuticals has a consensus target price of $58.78, suggesting a potential upside of 44.10%. Given BioXcel Therapeutics’ higher probable upside, equities analysts clearly believe BioXcel Therapeutics is more favorable than Xenon Pharmaceuticals.

Summary

Xenon Pharmaceuticals beats BioXcel Therapeutics on 10 of the 15 factors compared between the two stocks.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.